Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences (Nasdaq: NBIX) began a Phase 2 open-label, single-arm study of crinecerfont (CRENESSITY) in 20 children aged 3 months to under 4 years with classic congenital adrenal hyperplasia. The 24-week trial targets safety/tolerability and will assess PK/PD biomarkers, aiming to support a supplemental NDA to expand the U.S. indication. Enrollment also reached target in a EU Phase 2 study for birth to under 2 years.
How this was made
The 30-second read
Why it matters
Initiating Phase 2 in under-4s is intended to generate safety/tolerability and PK/PD evidence to expand the U.S. indication via a supplemental NDA, potentially broadening the addressable pediatric population.
Market read
Traders may view this as a development milestone that improves the probability of future label expansion, but the lack of results keeps the immediate impact moderate.
What to watch
Key swing factors are enrollment speed (20 patients, open-label), FDA Pediatric Written Request requirements, and whether PK/PD and safety in infants/toddlers translate into a supportable supplemental NDA.
Background
Crinecerfont (CRENESSITY) is already approved for classic CAH in patients 4+ as an adjunct to glucocorticoid replacement; this update targets younger children where no approved therapies exist.
Ticker impact
Neurocrine initiated a Phase 2 open-label, single-arm study of crinecerfont in children under 4 with classic CAH, aiming to support a supplemental NDA.
Likely modest positive bias for NBIX on the headline, with follow-through dependent on enrollment pace and future safety/PK/PD readouts.
This is a primary, time-stamped clinical development update (Phase 2 start) tied to an explicit regulatory objective (supplemental NDA for <4). However, no interim data or endpoints are provided, limiting immediate valuation impact.
Market effects
Reinforces ongoing competitive focus in pediatric endocrine rare diseases and non-glucocorticoid approaches to CAH management.
No direct regional market linkage beyond EU enrollment target for a separate Phase 2 cohort.
Supports global label-expansion strategy for crinecerfont across pediatric age bands, potentially affecting future payer/market access discussions.
Counterpoint
A Phase 2 start is progress, but without early data it may not change near-term expectations; investors may wait for safety/biomarker signals before repricing.
Key entities
- companyNeurocrine Biosciences, Inc.
Initiated Phase 2 study of crinecerfont in children 3 months to under 4 with classic CAH under an FDA Pediatric Written Request.
- drugcrinecerfont (CRENESSITY)
Oral CRF1 antagonist designed to reduce ACTH and adrenal androgens via a non-glucocorticoid mechanism.
- regulatoryFDA Pediatric Written Request
Framework under which the pediatric Phase 2 study is being conducted to support label expansion.
